viewSkylight Health Group Inc

CB2 Insights set to support multi-state operator Vireo Health in medical cannabis clinical trial

It will focus on Vireo’s line of products, currently available in Minnesota, but scheduled to launch in other markets this year

CB2 Insights Inc. -
Vireo will also license CB2 Insights' cloud-based data-analytics platform 'Sail' for full data collection and management

CB2 Insights Inc (CSE:CBII) (OTCMKTS:CBIIF) revealed that it is partnering with licensed producer and multi-state operator Vireo Health International to support a clinical trial for medical cannabis treatments in the US. 

It marks the start of the clinical trial process for Vireo’s topical creams, lotions and gels to be used by patients for pain management. 

The study will focus on Vireo’s line of products, which are currently available in Minnesota but are scheduled to launch in other markets this year.

READ: CB2 Insights CEO says company is on track to profitability in 2Q

CB2 Insights will manage the process of designing the protocol and working with the FDA on IND (Investigational New Drug) application approval. The initial stage of the project is earmarked to be completed by the first quarter of 2020.

"As we have seen with the FDA over the past year, they are steadfast in ensuring that cannabis-based medicines follow the same protocols as other traditional pharmaceuticals," said Prad Sekar, CEO of CB2 Insights.

"We are proud to have been chosen to advance that process with Vireo as we move forward with the IND application."

Vireo will also license CB2 Insights' cloud-based data-analytics platform 'Sail' for full data collection and management, the firm said in Tuesday's statement.

CB2 Insights has active technology, data and research projects in North America, the UK and Colombia.

Product commercialization

It can support licensed producers, multi-state operators from pre-clinical trial activities through to product commercialization.

The company operates the largest multi-state cannabis evaluation and education centers in the US, overseeing the care of more than 100,000 patients.

Sharesd added 4% to stand at C$0.13 in Toronto.

Contact the author at giles@proactiveinvestors.com

Quick facts: Skylight Health Group Inc

Price: - -

Market: CSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Skylight Health Group Inc named herein, including the promotion by the Company of Skylight Health Group Inc in any Content on the Site, the...


Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 17/12/19

2 min read